- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02478359
Walk On! Physical Activity Coaching
Patient-Centered Physical Activity Coaching in COPD: A Pragmatic Trial
Chronic obstructive pulmonary disease (COPD) is the third leading cause of the death in the US. The personal, social and economic costs of the disease are tremendous, with annual expenditures of nearly $50 billion, mostly from hospitalizations for exacerbations of COPD and associated sequelae. For the vast majority of patients, despite optimal pharmacological therapy, living with COPD is characterized by unrelieved dyspnea, physical inactivity, deconditioning, and an insidious downward spiral of social isolation and depression that has a profound impact on the lives of patients and their caregivers. There is mounting evidence that physical inactivity is significantly associated with more frequent hospitalizations and increased mortality in COPD even after adjusting for disease severity.
While practice guidelines recommend regular physical activity for all patients with COPD, health systems are challenged in operationalizing an effective and sustainable approach to assist patients in being physically active. The investigators propose a pragmatic randomized controlled trial to determine the effectiveness of a 12-month physical activity coaching intervention (Walk On!) compared to standard care for 1,650 COPD patients from a large integrated health care system.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Physical inactivity is significantly associated with more frequent hospitalizations and increased mortality in COPD even after adjusting for disease severity. While practice guidelines recommend regular physical activity for all patients with COPD, health systems are challenged in operationalizing an effective and sustainable approach to assist patients in being physically active.
A pragmatic randomized controlled trial design will be used to determine the effectiveness of a 12-month home and community-based physical activity coaching intervention (Walk On!) compared to standard care for 2,700 COPD patients from a large integrated health care system. Eligible patients with a COPD-related hospitalization, emergency department visit, or observational stay in the previous 12 months will be automatically identified from the electronic medical records (EMR) system and randomized to treatment arms. The Walk On! intervention includes collaborative monitoring of step counts, semi-automated step goal recommendations, individualized reinforcement from a physical activity coach, and peer/family support.
The primary composite outcome includes all-cause hospitalizations, emergency department visits, observational stays, and death in the 12 months following randomization. Secondary outcomes include COPD-related utilization, cardio-metabolic markers, physical activity, symptoms, and health-related quality of life. With the exception of patient reported outcomes, all utilization and clinical variables will be automatically captured from the EMR.
If successful, findings from this multi-stakeholder driven trial of a generalizable and scalable physical activity intervention model, carefully designed with sufficient flexibility, intensity, duration, and support for a large ethnically diverse sample could re-define the standard of care to effectively address physical inactivity in COPD.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Pasadena, California, United States, 91101
- Kaiser Permanente Southern California
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with any COPD-related hospitalization, emergency department visit or observational stay in the previous 12 months are eligible for the study. COPD-related encounters are defined according to the Centers for Medicare and Medicaid Services (CMS) and National Quality Forum (NQF) criteria for the Hospital Readmission Reduction Program. The following principal discharge diagnoses of COPD (ICD-9 codes: 491.21, 491.22, 491.8, 491.9, 492.8, 493.20, 493.21, 493.22, and 496) or respiratory failure (ICD-9 codes: 518.81, 518.82, 518.84, 799.1) with a secondary diagnosis of COPD exacerbation (ICD-9 codes: 491.21, 491.22, 493.21, 493.22) will be used
- Age >40 years
- On at least a bronchodilator or steroid inhaler prior to the encounter or if not on an inhaler, had a previous COPD diagnosis
- Continuous health plan membership in the 12 months prior to the encounter
Exclusion Criteria:
- FEV1/FVC ratio >0.70 at any point in the past year for those with spirometry data
- Discharged to hospice, a skilled nursing facility, long term-care or another acute care hospital during the index admission
- Level of function at admission or discharge during the index admission is bed bound
- Has Alzheimers disease, dementia or metastatic cancer
- Morbidly obese (BMI >40)
- Completed pulmonary rehabilitation in the last 6 months
- Deceased
- Dis-enrolled from the health plan
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Standard Care
Standard care patients received their routine care from Kaiser Permanente Southern California and had access to all health services in accordance with their health plan
|
|
|
Experimental: Physical Activity Coaching (Walk On!)
The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
|
The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With All-cause Hospitalizations, Emergency Department (ED) Visits, Observation Stays, and Deaths
Time Frame: 12 months following randomization
|
Covariates included in the adjusted multivariate models were age, FEV1% predicted, Charlson comorbidity index, oxygen use, hospitalization for COPD in previous 12 months, outpatient treated COPD exacerbation in previous 12 months, length of time since acute care utilization to randomization, use of LABA or ICS, PA level and study site
|
12 months following randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Deaths Among Participants
Time Frame: 12 months following randomization
|
Covariates included in the adjusted multivariate models were age, FEV1% predicted, Charlson comorbidity index, oxygen use, hospitalization for COPD in previous 12 months, outpatient treated COPD exacerbation in previous 12 months, length of time since acute care utilization to randomization, use of LABA or ICS, PA level and study site
|
12 months following randomization
|
|
Number of Participants With All-cause Hospitalizations
Time Frame: 12 months following randomization
|
Covariates included in the adjusted multivariate models were age, FEV1% predicted, Charlson comorbidity index, oxygen use, hospitalization for COPD in previous 12 months, outpatient treated COPD exacerbation in previous 12 months, length of time since acute care utilization to randomization, use of LABA or ICS, PA level and study site
|
12 months following randomization
|
|
Number of Participants With All-cause Emergency Department Visits
Time Frame: 12 months following randomization
|
Covariates included in the adjusted multivariate models were age, FEV1% predicted, Charlson comorbidity index, oxygen use, hospitalization for COPD in previous 12 months, outpatient treated COPD exacerbation in previous 12 months, length of time since acute care utilization to randomization, use of LABA or ICS, PA level and study site
|
12 months following randomization
|
|
Number of Participants With All-cause Observation Stays
Time Frame: 12 months following randomization
|
Covariates included in the adjusted multivariate models were age, FEV1% predicted, Charlson comorbidity index, oxygen use, hospitalization for COPD in previous 12 months, outpatient treated COPD exacerbation in previous 12 months, length of time since acute care utilization to randomization, use of LABA or ICS, PA level and study site
|
12 months following randomization
|
|
Number of Participants With COPD-Related Hospitalizations, ED Visits, and Observation Stays
Time Frame: 12 months following randomization
|
Covariates included in the adjusted multivariate models were age, FEV1% predicted, Charlson comorbidity index, oxygen use, hospitalization for COPD in previous 12 months, outpatient treated COPD exacerbation in previous 12 months, length of time since acute care utilization to randomization, use of LABA or ICS, PA level and study site
|
12 months following randomization
|
|
Number of Participants With COPD Exacerbation
Time Frame: 12 months following randomization
|
COPD exacerbations were ascertained via pharmacy records and utilization data.
An outpatient COPD exacerbation will be defined as a care touch (clinic visit, phone, or secure message encounter) with a diagnosis of COPD accompanied by a prescription of either an oral steroid or an antibiotic within 2 days
|
12 months following randomization
|
|
COPD Assessment Test, CAT - 12 Months
Time Frame: 12 months
|
The reported mean change between the baseline and 12 Months scores for the Chronic Obstructive Pulmonary Disease Assessment Test (CAT).
Score range is 0-40.
A negative change score indicates fewer symptoms.
|
12 months
|
|
Physical Activity
Time Frame: 12 months
|
Patients were categorized as being: completely inactive (0 mins/week), insufficiently active (1-149 mins/week) or active, meeting national physical activity recommendations (>150 mins/week) of moderate to vigorous physical activity.
|
12 months
|
|
Personal Health Questionnaire, PHQ8 - 12 Months
Time Frame: 12 months
|
The reported mean change between the baseline and 12 Months scores.
Score range is 0-24.
A negative change score indicates less depressive symptoms.
|
12 months
|
|
General Anxiety Disorder, GAD-7 - 12 Months
Time Frame: 12 months
|
The reported mean change between the baseline and 12 Months scores.
Score range is 0-21.
A negative change score indicates less anxiety.
|
12 months
|
|
PROMIS-10 HRQL , Physical Health - 12 Months
Time Frame: 12 months
|
The reported mean change between the baseline and 12 Months T-scores.
Score range is 16-68.
A positive change score reflects better physical functioning.
|
12 months
|
|
PROMIS-10 HRQL , Mental Health - 12 Months
Time Frame: 12 months
|
The reported mean change between the baseline and 12 Months T-scores.
Score range is 21-68.
A positive change score reflects better mental health.
|
12 months
|
|
Diastolic Blood Pressure
Time Frame: 12 months following randomization
|
Average of all routine clinic blood pressure reading taken between 6 and 12-months post randomization.
BP obtained with temperatures of >100F and those obtained in urgent care were excluded.
|
12 months following randomization
|
|
Systolic Blood Pressure
Time Frame: 12 months following randomization
|
Average of all routine clinic blood pressure reading taken between 6 and 12-months post randomization.
BP obtained with temperatures of >100F and those obtained in urgent care were excluded.
|
12 months following randomization
|
|
HbA1c Levels
Time Frame: 12 months following randomization
|
HbA1c levels were obtained only from diabetics and on values closest to the 12 months post randomization
|
12 months following randomization
|
|
LDL Levels
Time Frame: 12 months following randomization
|
Cholesterol levels were obtained from values closest to the 12 months post randomization
|
12 months following randomization
|
|
HDL Levels
Time Frame: 12 months following randomization
|
Cholesterol levels were obtained from values closest to the 12 months post randomization
|
12 months following randomization
|
|
Total Cholesterol Levels
Time Frame: 12 months following randomization
|
Cholesterol levels were obtained from values closest to the 12 months post randomization
|
12 months following randomization
|
|
Triglycerides Levels
Time Frame: 12 months post randomization
|
Cholesterol levels were obtained from values closest to the 12 months post randomization
|
12 months post randomization
|
|
Body Mass Index
Time Frame: 12 months following randomization
|
Body mass index measurements were based on values closest to the 12 months post randomization
|
12 months following randomization
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With All-cause Hospitalization, Emergency Department (ED) Visits, Observation Stays and Deaths
Time Frame: 2 to 12 months following randomization
|
As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group.
The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention.
|
2 to 12 months following randomization
|
|
Number of Deaths Among Participants
Time Frame: 2 to 12 months following randomization
|
As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group.
The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention.
|
2 to 12 months following randomization
|
|
Number of Participants With All-cause Hospitalizations
Time Frame: 2 to 12 months following randomization
|
As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group.
The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention.
|
2 to 12 months following randomization
|
|
Number of Participants With All-cause Emergency Department Visits
Time Frame: 2 to 12 months following randomization
|
As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group.
The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention.
|
2 to 12 months following randomization
|
|
Number of Participants With All-cause Observation Stays
Time Frame: 2 to 12 months following randomization
|
As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group.
The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention.
|
2 to 12 months following randomization
|
|
Number of Participants With COPD-Related Hospitalizations, ED Visits, and Observation Stays
Time Frame: 2 to 12 months randomization
|
As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group.
The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention.
|
2 to 12 months randomization
|
|
Diastolic Blood Pressure
Time Frame: 6-12 months following randomization
|
Average of all routine clinic blood pressure reading taken between 6 and 12-months post randomization.
BP obtained with temperatures of >100F and those obtained in urgent care were excluded.
|
6-12 months following randomization
|
|
Systolic Blood Pressure
Time Frame: 6-12 months following randomization
|
Average of all routine clinic blood pressure reading taken between 6 and 12-months post randomization.
BP obtained with temperatures of >100F and those obtained in urgent care were excluded.
|
6-12 months following randomization
|
|
HbA1c Levels
Time Frame: 12 months
|
HbA1c levels were obtained only from diabetics and on values closest to the 12 months post randomization
|
12 months
|
|
LDL Levels
Time Frame: 12 months
|
Cholesterol levels were obtained from values closest to the 12 months post randomization
|
12 months
|
|
HDL Levels
Time Frame: 12 months
|
Cholesterol levels were obtained from values closest to the 12 months post randomization
|
12 months
|
|
Total Cholesterol Levels
Time Frame: 12 months
|
Cholesterol levels were obtained from values closest to the 12 months post randomization
|
12 months
|
|
Triglycerides Levels
Time Frame: 12 months
|
Cholesterol levels were obtained from values closest to the 12 months post randomization
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Huong Q Nguyen, PhD, RN, Research Scientist
Publications and helpful links
General Publications
- Nguyen HQ, Bailey A, Coleman KJ, Desai S, Fan VS, Gould MK, Maddock L, Miller K, Towner W, Xiang AH, Moy ML. Patient-centered physical activity coaching in COPD (Walk On!): A study protocol for a pragmatic randomized controlled trial. Contemp Clin Trials. 2016 Jan;46:18-29. doi: 10.1016/j.cct.2015.10.010. Epub 2015 Oct 24.
- Nguyen HQ, Moy ML, Fan VS, Gould MK, Xiang A, Bailey A, Desai S, Coleman KJ. Applying the pragmatic-explanatory continuum indicator summary to the implementation of a physical activity coaching trial in chronic obstructive pulmonary disease. Nurs Outlook. 2018 Sep;66(5):455-463. doi: 10.1016/j.outlook.2018.05.005. Epub 2018 Jul 12.
- Nguyen HQ, Moy ML, Liu IA, Fan VS, Gould MK, Desai SA, Towner WJ, Yuen G, Lee JS, Park SJ, Xiang AH. Effect of Physical Activity Coaching on Acute Care and Survival Among Patients With Chronic Obstructive Pulmonary Disease: A Pragmatic Randomized Clinical Trial. JAMA Netw Open. 2019 Aug 2;2(8):e199657. doi: 10.1001/jamanetworkopen.2019.9657.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KPSC IRB 12345
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD)
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Ryme Medical, Inc.Not yet recruitingCOPD | Lung Disease, Chronic Obstructive | COPD Patients | COPD Acute Exacerbation | COPD (Chronic Obstructive Pulmonary Disease) | Lung Disease Airways | COPD Exacerbations
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Morair Medtech, LLCRecruitingEmphysema | COPD | Emphysema or COPD | COPD (Chronic Obstructive Pulmonary Disease) | Emphysema, PulmonaryAustria, Germany, Netherlands
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Barron Associates, Inc.National Heart, Lung, and Blood Institute (NHLBI); University of VirginiaNot yet recruitingCOPD | COPD - Chronic Obstructive Pulmonary DiseaseUnited States
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
Clinical Trials on Physical Activity Coaching (Walk On!)
-
Teachers College, Columbia UniversityCompletedParkinson's DiseaseUnited States
-
Universitaire Ziekenhuizen KU LeuvenDutch Health Care Insurance BoardCompletedDiabetes Mellitus, Type 2Belgium
-
Teachers College, Columbia UniversityActive, not recruitingCerebellar AtaxiaUnited States
-
Stanford UniversityGoogle LLC.WithdrawnCardiovascular HealthUnited States
-
University of MinnesotaCompleted
-
Teachers College, Columbia UniversityColumbia UniversityActive, not recruitingParkinson DiseaseUnited States
-
Teachers College, Columbia UniversityCompleted
-
University of Maryland, BaltimoreNational Institute on Aging (NIA)Completed
-
University Hospital, Clermont-FerrandLaboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques... and other collaboratorsUnknownParkinson's DiseaseFrance
-
Region StockholmKarolinska InstitutetActive, not recruitingMental DisordersSweden